There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

Detailed price information for Meta Platforms Inc (META-Q) from The Globe and Mail including charting and trades.

Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions and more booze-free ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...